Teicoplanin, a new glycopeptide antibiotic, has been used to treat twelve patients with bacterial endocarditis due to Gram-positive organisms. Teicoplanin has activity against Gram-positive bacteria similar to vancomycin but therapeutic levels are maintained by a single daily dose, given as an intravenous bolus.
Introduction
Infective endocarditis is an uncommon disease, but is still associated with considerable morbidity and mortality. More than 80% of infections are caused by Gram-positive organisms,' for which there are several generally accepted alternative treatments, including beta-lactams, aminoglycosides, rifampicin and van- comycin. The wider use of vancomycin has been limited by fears of nephro-toxicity and oto-toxicity and difficulty of administration.
Teicoplanin is structurally related to vancomycin, and is active against almost all Gram-positive organisms.2 In vitro, its activity is similar to vancomycin but its longer serum half-life of 47 hours allows administration as a single daily injection by the intravenous route. On the strength ofthese properties, teicoplanin has been used in combination with other antimicrobial agents in the treatment of twelve cases of infective endocarditis.
Methods
Bacterial isolates from blood cultures were identified in the usual fashion. Minimum inhibitory and bactericidal concentrations (MIC and MBC) of the antibiotics used were determined for all isolates using a two-fold tube dilution method in nutrient broth, supplemented by 10% horse serum depending upon growth requirements, using an inoculum of approximately 5 x I05 cfu/ml. Tubes Vancomycin is one of the most commonly used antibiotics in the treatment of infective endocarditis due to methicillin-resistant staphylococci or in patients with a history ofallergy to penicillin.8 Ototox- Teicoplanin, a new glycopeptide antibiotic, has a similar mode of action to vancomycin and is bactericidal at therapeutic concentrations for the majority of Gram-positive bacteria.'0" In a rabbit model of endocarditis, it is bacteriostatic for Streptococcus faecalis when used alone but it shows a marked synergy with gentamicin'2 and it is as effective as vancomycin against methicillin-resistant Staphylococcus aureus.'3 However, teicoplanin is potentially a more attractive choice in the treatment ofendocarditis because it can be given as a single daily intravenous bolus without causing thrombophlebitis.'°Toxicology studies in dogs show that renal damage occurs only at high dosage levels (40 mg/kg) and is less marked than with vancomycin.'°I n the present study, all five cases of infective endocarditis caused by penicillin-sensitive streptococci, were cured, including three prosthetic valve infections. Two received teicoplanin as the sole therapy, two received an initial 2 weeks gentamicin therapy, and the fifth patient received prolonged combination chemotherapy. Cure was also achieved in both cases of enterococcal infective endocarditis, although both received gentamicin for 2 to 3 weeks.
The use of teicoplanin appeared less successful in infections caused by staphylococci, despite combination chemotherapy. However, relapses in the two cases of endocarditis due to Staphylococcus aureus were probably related to continued drug abuse and existing therapy for prosthetic valve endocarditis due to Staphylococcus epidermidis also has a poor outcome. 5 The only patient with infection due to methicillin-resistant staphylococci succumbed despite aggressive chemotherapy.
In this series, the use ofteicoplanin resulted in a high tone hearing loss in one patient, which has been reported elsewhere,3 and in drug-induced fever in another. However, neither adverse reaction affected the eventual outcome. Vestibular damage in a third patient was more debilitating but, in the presence of high levels of aminoglycoside, the role of teicoplanin was difficult to assess.
Trough bactericidal titres were not helpful in predicting outcome in this study. Weinstein6 found that if laboratory variables are controlled, a trough bactericidal titre >1:8 had a predictive value of bacteriological cure of 98%. However, titres of < 1:8 had a predictive value of only 21% for failure, and bactericidal titres had no correlation with clinical outcome.
In these 12 
